Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPOSE: Intravaginal Prasterone for Genitourinary Syndrome in Women with Breast Cancer History or on Aromatase Inhibitors
2023-506211-18-00Phase 3Authorised
- Sponsor
- European Institute of Oncology
- Start
- Jul 2024
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of dehydroepiandrosterone in vaginal atrophy, sponsored by European Institute of Oncology. Primary endpoint: Subjective improvement of genitourinary symptoms. Planned start Jul 2024; status: authorised.
02
Drugs
dehydroepiandrosterone
03
Conditions
vaginal atrophy
Beyond the preview
Go deeper on 2023-506211-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506211-18-00.